Julia Mirer M.D.

Julia Mirer MD currently serves as the Director of Strategy at NeuroPain Health and is a member of the Board of Directors for End of Life Psychedelic Care. Julia has held multiple strategic and advisory roles, including Director of Strategy and Impact at Nushama, Research Coordinator at the Ibogaine Research Institute, and various advisory positions at PsiloHealth and the Diaspora Psychedelic Society. Notably, Julia was the Chief Education Officer at Mr. Psychedelic Law and facilitated a phase 2 clinical trial for psilocybin at Segal Trials. Julia earned a Doctor of Medicine degree from Ross University School of Medicine and a Bachelor of Arts degree in Pre-Medicine from Hofstra University.